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SUMMARY 
Pro-inflammatory cytokines of a T helper-1-signature are known to promote insulin 
resistance (IR) in obesity, but the physiological role of this mechanism is unclear. It is also 
unknown whether and how viral infection induces loss of glycemic control in subjects at risk 
for developing diabetes mellitus type 2 (DM2). We have found in mice and humans that viral 
infection caused short-term systemic IR. Virally-induced interferon- directly targeted skeletal 
muscle to downregulate insulin receptor but did not cause loss of glycemic control because of 
a compensatory increase of insulin production. Hyperinsulinemia enhanced antiviral immunity 
through direct stimulation of CD8+ effector T cell function. In pre-diabetic mice with hepatic 
IR caused by diet-induced obesity, infection resulted in loss of glycemic control. Thus, upon 
pathogen encounter, the immune system transiently reduces insulin sensitivity of skeletal 
muscle to induce hyperinsulinemia and promote antiviral immunity, which derails to glucose 
intolerance in pre-diabetic obese subjects.  
INTRODUCTION 
Diabetes mellitus type 2 (DM2) is a highly prevalent (Stevens et al., 2012) metabolic 
disease, characterized by high blood glucose concentrations. The pathology of DM2 involves 
many organs but its main underlying mechanism is decreased insulin sensitivity of the liver 
and skeletal muscle and an inability of pancreatic -cells to compensate for this defect 
(Defronzo, 2009). DM2 is diagnosed based on increased concentrations of glycosylated 
hemoglobin (HbA1c), fasting plasma glucose (FPG) or postprandial blood glucose (American 
Diabetes, 2018). If these concentrations are increased, but do not reach DM2 threshold values, 
people are diagnosed with pre-diabetes (Abdul-Ghani et al., 2006). Prospective studies show 
that changes in glycemic control occur gradually over years, but typically contain an abrupt 
increase in metabolic parameters preceding diagnosis of DM2 (Mason et al., 2007; Tabak et 
al., 2012). Progression from pre-diabetes to DM2 therefore appears to involve an unknown 
“event” that pushes systemic insulin resistance (IR) beyond the ability of the pancreas to 
compensate. DM2 is associated with chronic systemic low-grade inflammation originating in 
visceral adipose tissue (VAT) (Wensveen et al., 2015b). Obese VAT accumulates pro-
inflammatory immune cells and drives a Type-1 immune response, normally associated with 
viral infection, characterized by the production of cytokines such as tumor necrosis factor 
(TNF) and interleukin 1 (IL-1β) (Johnson et al., 2012; Wensveen et al., 2015a; Wensveen et 
al., 2015b). Obesity thus mimics a state of chronic systemic low-grade infection and leakage 
of pro-inflammatory cytokines into circulation is thought to contribute to systemic IR (Johnson 
et al., 2012; Wensveen et al., 2015b). Acute infection may therefore represent the “event” that 
drives rapid progression to DM2 in pre-diabetes. Only few epidemiological studies address this 
topic and these do suggest that infection is associated with a higher risk of DM2 (Chen et al., 
2012; Leinonen and Saikku, 1999; Roberts and Cech, 2005). However, direct experimental 
evidence if and how infection impacts glycemic control are lacking. 
It is currently unclear what the physiological role is of reduced systemic insulin 
sensitivity following infection. Immune activation comes at a considerable energetic cost 
(Ganeshan and Chawla, 2014), as cells switch from oxidative to glycolytic metabolism (O'Neill 
et al., 2016). It was therefore proposed that inflammation-induced IR is a physiological 
response to infection that aims to increase systemic glucose availability to activated immune 
cells (Kotas and Medzhitov, 2015). However, infection-induced acute loss of glycemic control 
is only observed under extreme conditions such as sepsis, whereas DM2 is associated only with 
low amounts of systemic inflammation (Johnson et al., 2012; Marik and Raghavan, 2004). 
Alternatively, inflammation-induced IR may be a strategy of the immune system to involve 
endocrine mediators in the response against infection. Both cytokines and hormones regulate 
the metabolism of cells in response to alterations in the external environment. Frequently their 
receptors overlap both in the intracellular signaling pathways that they use and the effects that 
they mediate (Ouchi et al., 2011). For example, receptors for both IL-6 and for the adipose 
tissue-derived hormone leptin signal through the Jak2-Stat3 signaling pathway (Heinrich et al., 
2003; Munzberg and Morrison, 2015) and both molecules promote proliferation of immune 
cells and excretion of cytokines by macrophages (Heinrich et al., 2003). The insulin receptor 
shares its downstream signaling cascade with CD28, one of the most potent costimulatory 
molecules for CD8+ T cells (Pessin and Saltiel, 2000; Sharpe and Freeman, 2002). Both 
pathways converge on phosphatidylinositol 3 kinase (PI3K), enhancing anabolic metabolism 
and increasing glucose transporter amounts on the cell membrane (Frauwirth et al., 2002; 
Pessin and Saltiel, 2000). IR is associated with hyperinsulinemia. Whether insulin plays a role 
in promoting immune responses following infection is unknown. 
Here, we investigated how infection impacts insulin-mediated regulation of glycemia. 
We found that virally-induced IFN caused IR in the skeletal muscle through direct 
engagement of the IFN-γ receptor on myocytes and down-modulation of the insulin receptor 
on these cells. Infection-induced selective IR drove an increase of systemic insulin 
concentrations to prevent hyperglycemia, but also to boost the anti-viral CD8+ T cell response 
through direct promotion of effector cell function. When systemic insulin sensitivity is already 
reduced, such as in pre-diabetic obese subjects due to hepatic IR, infection overwhelmed the 
ability of the endocrine system to compensate for increased muscle IR and glucose intolerance 
(GI) ensues. We thus identify an immune-endocrine regulatory feed-back mechanism of 
antiviral immunity and provide additional insights in the underlying physiology of DM2. 
 
RESULTS 
Viral infection causes development of insulin resistance, but not glucose intolerance 
First, we investigated whether infection impacts systemic metabolic parameters in 
humans. Body mass index (BMI) and blood parameters were obtained from euglycemic people 
with normal weight (BMI of 18-25 kg/m2) and overweight (BMI >25), diagnosed with acute 
respiratory infection at time of presentation of symptoms and three months later. Infection 
transiently increased fasting plasma insulin (FPI) in both groups (Figure 1A). In contrast, FPG 
was not significantly affected by infection (Figure 1B). Notably, the homeostasis model 
assessment – insulin resistance (HOMA-IR) index values, which inversely correlate with 
systemic insulin sensitivity, were increased during acute infection, especially for people with 
overweight (Figure 1C). Thus, acute infection appeared to transiently decrease systemic 
insulin sensitivity in humans, without affecting blood glucose concentrations. 
We next used murine cytomegalovirus (MCMV) as an animal model for a common 
human infection (Krmpotic et al., 2003). MCMV has a broad tropism, including key organs 
involved in the regulation of glucose homeostasis, such as liver, VAT, pancreas and skeletal 
muscle (Figure 1D). Animals were infected with MCMV and after seven days subjected to an 
insulin tolerance test (ITT). We observed that MCMV infection resulted in transient intolerance 
to insulin (Figure 1E; S1A). To confirm that this effect was the result of IR, mice were 
subjected to hyperinsulinemic-euglycemic clamping on day five after infection. Indeed, 
infected animals showed a strongly reduced sensitivity to insulin in comparison to non-infected 
controls (Figure 1F; S1B), as determined by a lower glucose infusion rate (GIR). To determine 
whether infection-induced IR resulted in loss of glycemic control, infected animals were 
analyzed by glucose tolerance test (GTT). Despite IR, infection did not result in GI (Figure 
1G). As in humans, infection was associated with elevated FPI concentrations. Moreover, 
following glucose challenge, increased insulin production was observed in infected animals, 
explaining why systemic IR does not result in GI (Figure 1H).  
Taken together, human and mouse data show that infection transiently induces IR, but 
does not result in overt GI due to compensatory hyperinsulinemia. 
 
Viral infection enhances progression of diabetes mellitus type 2 in obesity 
Systemic IR is the underlying cause of DM2. However, people are only diagnosed as 
diabetics when systemic IR has reached a level at which compensatory mechanisms fail to 
lower blood glucose concentrations below well-defined threshold. Thus, DM2 is diagnosed by 
measuring GI, rather than IR. In pre-diabetes, frequently an unknown “event” drives rapid 
development of DM2 (Tabak et al., 2012). To see whether infection represents such an event, 
animals were placed on a diet with high fat-content (HFD), resulting in diet-induced obesity 
(DIO). HFD generates systemic IR and GI in three months (Wensveen et al., 2015a), but after 
6 weeks results only in hepatic IR, characterized by increased FPG and pyruvate intolerance 
(Figure S1C, D), but not yet systemic IR or GI (Figure S1E, F), thus resembling human pre-
diabetes (Mason et al., 2007). Infection of 6 weeks HFD-primed (`pre-diabetic`) mice with 
MCMV resulted in both IR and GI (Figure 1I, J), but did not affect obesity (Figure S1G). To 
test whether other viral pathogens also affect glucose homeostasis, we infected pre-diabetic 
mice with lymphocytic choriomeningitis (LCMV) or Influenza A virus. Both infections 
resulted in similar loss of glucose control as observed after MCMV infection (Figure S1H, I).  
An important question from the perspective of clinical relevance is whether the impact 
of infection on glycemic control is transient or permanent. Indeed, we observed that three 
weeks after MCMV infection, pre-diabetic mice still showed increased GI (Figure 1K) 
although there was no difference in viral titers between normal chow diet (NCD) or HFD fed 
animals (Figure S1J), suggesting a long-lasting effect. When MCMV infection and HFD 
feeding were started on the same day, increased IR and reduced glycemic control were 
observed for at least 8 weeks in infected animals, compared to non-infected controls (Figure 
1L, M). In contrast, the impact of Influenza A or LCMV infection on glucose intolerance of 
HFD-primed animals appeared to be transient (Figure S1K, L).  
Chronic uncontrolled DM2 is associated with development of microvascular and 
macrovascular complications, such as diabetic nephropathy (DN). To investigate whether 
infection aggravates development of DM2-associated complications, animals were infected 
with MCMV on the same day when we started with HFD feeding. At 16 weeks, infection of 
pre-diabetic mice promoted hypertrophy of juxtamedullary glomeruli, an early sign of DN 
(Shahbazian and Rezaii, 2013) (Figure 1N). After 24 weeks, histological analysis revealed 
more severe symptoms of DN in 10-20% of glomeruli of infected HFD-fed mice, but not in 
lean or uninfected animals, whereas kidneys from obese mice were mildly affected in only 5% 
of glomeruli (Figure 1O; S1M). 24 weeks after infection, viral replication was not detectible 
in kidneys of mice fed either with NCD or HFD, indicating that virus-induced pathology is not 
directly responsible for DN (Figure S1N). In addition, infection with MCMV in HFD fed 
animals resulted in increased thickness of the basement membrane, another bona fide marker 
of DN (Figure 1P).  
Our findings indicate that viral infection is an independent risk factor for development 
of diabetes by pre-diabetic obese individuals. To investigate whether we could therapeutically 
prevent GI in pre-diabetic mice, animals were treated with the antiviral drug ganciclovir 
starting one day after infection. Ganciclovir treatment strongly reduced viral replication 
(Figure S1O) and prevented development of virus-induced glucose intolerance in HFD primed 
mice (Figure 1Q).  
In summary, viral infection of “pre-diabetic” obese mice cause a reduction of glycemic 
control and aggravates development of clinical symptoms associated with DM2.  
 
Viral infection promotes development of glucose intolerance and insulin resistance 
through interferon- 
To gain insight in the mechanism underlying virus-induced progression of DM2 we 
first investigated whether viral infection affects glucose sensing by the pancreas after HFD 
priming. We observed that infection of pre-diabetic mice with MCMV resulted in increased 
FPI and enhanced insulin production following glucose challenge (Figure 2A). To further 
prove that MCMV infection increases insulin secretion we calculated the insulinogenic index, 
which positively correlates with insulin output from pancreatic β-cells (Dalmas et al., 2017).  
We observed that the insulinogenic index was increased in infected, HFD-fed animals 
compared to controls, excluding pancreatic dysfunction as a cause for GI (Figure 2B).  
The liver has an important role in maintaining euglycemia through gluconeogenesis, 
glycogenolysis and glycogenesis. Liver diseases, including viral hepatitis, are therefore 
frequently associated with aberrations in glucose homeostasis (Barthel and Schmoll, 2003; 
Cotrozzi et al., 1997; Custro et al., 2001; Holstein et al., 2002; Picardi et al., 2006; Postic et al., 
2004; Tappy and Minehira, 2001). To investigate whether liver damage alone may be 
responsible for enhanced progression of GI in our model, pre-diabetic mice were exposed to 
the hepatotoxic compounds CCL4 (Boll et al., 2001) or paracetamol (Mossanen and Tacke, 
2015) (Figure S2A, B).  Neither compound induced development of GI in pre-diabetic animals 
(Figure S2C, D).  
We therefore considered the possibility that the immune system drives IR through 
specific cytokines following infection. Viral infection activates the inflammasome (Lamkanfi 
and Dixit, 2014), which generates the pro-diabetic cytokine IL-1 (Ballak et al., 2015). 
However, neither chemical inhibition of the NLRP3 inflammasome activity, nor neutralization 
of IL-1 with antibodies resulted in amelioration of GI following MCMV infection of pre-
diabetic mice (Figure S2E, F). In fact, neutralization of IL-1β increased glucose intolerance 
following infection, which corresponds with the previously reported positive effect of this 
cytokine on glycemic control (Dror et al., 2017). Type-1 inflammatory cytokines such as  
interferons and TNF, have a negative impact on glucose homeostasis in the context of obesity 
(Fensterl and Sen, 2009; Grzelkowska-Kowalczyk and Wieteska-Skrzeczynska, 2009; Kim 
and Solomon, 2010; Koivisto et al., 1989; McGillicuddy et al., 2009; Nieto-Vazquez et al., 
2008; Wada et al., 2011; Yki-Jarvinen et al., 1989). We therefore injected lean and pre-diabetic 
mice with Poly I: C, a strong inducer of type-1 interferons (Wu et al., 2014). Whereas this 
treatment did activate peritoneal macrophages, no impact on GI was observed (Figure S2G, 
H). TNF has been shown to induce IR in ob/ob mice through TNF receptor 1 (TNFR1) (Uysal 
et al., 1998). However, deficiency for TNFR1 did not result in amelioration of GI following 
MCMV infection of pre-diabetic animals (Figure S2I). In contrast, although neutralization of 
interferon- (IFN-) was associated with increased viral titers in some tissues important for 
glucose homeostasis (Figure S2J), neutralization of IFN- completely prevented GI and IR in 
MCMV and LCMV infected pre-diabetic animals (Figure 2C, D; S2K). Similar results were 
achieved in Ifng-/- mice (Figure S2L). This data shows that IFN- plays a dominant role in 
progression of DM2 induced by different viruses. 
IFN- is produced exclusively by immune cells (Schroder et al., 2004) following viral 
infection, in particular by NK cells, CD4+ and CD8+ T cells. We depleted NK, CD4+ or CD8+ 
T cells in MCMV infected, pre-diabetic mice (Figure 2E, F). Only elimination of NK cells 
resulted in a loss of GI (Figure 2F). To investigate whether NK cells have a prolonged effect 
on glycemic control in obese animals, we infected NK cell-depleted mice simultaneously with 
the start of HFD. Depletion of NK cells completely prevented development of GI 8 weeks after 
infection (Figure S2M). To confirm that NK cells drive GI through IFN, Ifng-/- mice received 
PBS or WT NK cells preceding MCMV infection. Only in the presence of WT NK cells, did 
Ifng-/-mice develop IR (Figure 2G). In addition, infection of HFD primed mice with m157-
deficient MCMV virus (Δm157), which precludes Ly49h-mediated activation of NK cells, did 
not induce development of GI (Figure S2N). Thus, MCMV infection drives development of 
GI and IR in pre-diabetic mice via NK cell-derived IFN- 
In summary, virally-induced IFN- promotes IR and GI and drives the rapid progression 
from pre-diabetes to DM2 in infected mice. 
 
 
Interferon- specifically induces insulin resistance of skeletal muscle cells  
To investigate whether systemic or local increase of IFN- concentrations is responsible 
for the effect, pre-diabetic mice were infected with MCMV and plasma IFN- concentrations 
were followed over time. We observed that increased blood IFN- returned to baseline at time 
points when it still impacted GI and IR (Figure 3A). This result suggests that IFN- either has 
a long-lasting effect on the ability of tissues to sense insulin, or that there is a local source of 
IFN- which sustains impairment of insulin sensitivity. We neutralized IFN- starting 7 days 
post infection (p.i.) of HFD primed mice, when its concentrations in the blood have returned 
to baseline. GI was completely prevented in treated mice (Figure 3B), which indicates that a 
local source of IFN- drove continued GI and IR in pre-diabetic mice following infection.   
Previously we showed that NK cell derived IFN- promotes IR in the DIO model by 
inducing M1 adipose tissue macrophage (ATM) polarization (Wensveen et al., 2015a). We 
hypothesized that this mechanism also operates in the context of infection. Whereas infection 
does enhance ATM conversion and tissue inflammation, clodronate-mediated neutralization of 
these cells did not prevent infection-induced GI (Figure S3A, B). To confirm that IFN- 
mediates its effect in infected mice independently of macrophages, we conditionally ablated 
the receptor for IFN- (IFNR1) on these cells. Lyz2creIfngr1flox/flox (Ifngr1ΔMac) and littermate 
controls were placed on HFD for 6 weeks and then infected with MCMV. Five days p.i. we 
observed no difference in insulin sensitivity (Figure 3C) or GI (Figure 3D) between Ifngr1ΔMac 
and littermate controls. Thus, IFN- mediates its effect on IR and GI in infected pre-diabetic 
mice independently of macrophages.  
We therefore considered that IFN- directly affects insulin sensitivity of one or more 
organs involved in glucose homeostasis. In the DIO model, VAT is the main source of chronic 
systemic inflammation and plays a key role in the development of IR and GI. We have shown 
previously that surgical removal of VAT (VATectomy) prevents development of GI and IR in 
non-infected obese mice (Wensveen et al., 2015a). We performed VATectomy two weeks 
before initiation of HFD feeding and MCMV infection. GTT was performed ten weeks after 
the surgery. As expected, VATectomy reduced glucose intolerance in non-infected animals. In 
contrast, removal of visceral fat pads was not able to prevent infection-induced GI (Figure 
3E). Since VATectomy does not remove all adipocyte deposits in mice, we conditionally 
ablated IFNR1 on adipocytes. Pre-diabetic Adipoqcre Ifngr1flox/flox mice (Ifngr1ΔAdi) were not 
able to prevent infection-induced IR or GI in comparison to littermate controls (Figure 3F, G). 
Thus, adipocytes do not play a major role in infection-induced GI in pre-diabetic mice. 
To investigate whether infection reduces insulin sensitivity of the liver, pre-diabetic 
mice were infected with MCMV. One-week p.i. we observed that DIO, but not infection 
increased FPG concentrations (Figure 3H). In addition, one-week p.i. we analyzed 
gluconeogenesis by pyruvate tolerance test (PTT). In line with FPG concentrations, we 
observed that HFD increased gluconeogenesis following pyruvate challenge. However, 
infection did not result in enhanced, but even in somewhat reduced gluconeogenesis (Figure 
3I). In addition, hepatocytes from HFD-fed mice showed reduced induction of AKT 
phosphorylation (pAKT) in response to insulin challenge compared to NCD-fed mice, whereas 
infection did not further impair this process (Figure 3J). Finally, hepatocyte-specific ablation 
of the IFNR1 using AlbcreIfngr1flox/flox animals (Ifngr1ΔHep) did not result in a reduction of IR 
or GI following infection of pre-diabetic mice (Figure S3C). To confirm that infection does 
not result in hepatic insulin resistance, we calculated endogenous glucose production rate 
(EGP) under basal conditions and after infusion of insulin during hyperinsulinemic-euglycemic 
clamp study. We did not observe an impact of infection on EGP under either condition (Figure 
3K). Thus, infection-induced IR and GI is mediated independently of macrophages, adipocytes 
and hepatocytes.  
Next, we considered skeletal muscle as a target tissue. Skeletal muscle is responsible 
for 70-75% of insulin-induced glucose absorption (DeFronzo et al., 1981; Shulman et al., 
1990).  We noticed that infection, but not DIO increases IFN- transcription in skeletal muscle 
seven days post infection (Figure S4). Therefore, we hypothesized that infection directly 
targets insulin sensitivity of muscle cells. Indeed, we observed that infection reduced pAKT in 
muscle of lean and obese animals upon insulin challenge (Figure 4A). This effect was IFN--
dependent, since we did not observe this effect in Ifng-/- mice (Figure 4B). Moreover, 
CkmcreIfngr1flox/flox mice (Ifngr1ΔMyo), which lack the IFNR1 receptor on myocytes, were 
protected from infection-induced IR and GI (Figure 4C). To demonstrate that infection 
specifically impairs glucose uptake into skeletal muscle in response to insulin, mice were 
subjected to hyperinsulinemic-euglycemic clamping and were injected with a bolus of 
radioactive 2-deoxy glucose at the end of the steady state period. We noted that glucose uptake 
in muscle was strongly reduced following infection, whereas internalization in VAT was not 
affected (Figure 4D). 
These results demonstrate that skeletal muscle cells are the main targets of IFN-
 induced IR and progression of DM2 following infection.  
 
Interferon- drives insulin resistance of skeletal muscle cells through downregulation of 
the insulin receptor 
Next, we sought to elucidate how infection-induced IFN-γ drives IR in muscle. 
Infection did not affect total Akt protein expression, suggesting that IFN- impairs upstream 
insulin receptor signaling. No differences were observed in transcription of Irs1 and Irs2 
(Figure S5A). Also, we found no increase in Socs1 or Socs3, which are known targets of IFN-
γ and known inhibitors of insulin signaling (Wormald et al., 2006) (Figure S5B). In contrast, 
transcription of Insr, coding for the insulin receptor, was significantly reduced in muscle, but 
not in liver of infected pre-diabetic mice (Figure 5A). Moreover, we found that infection of 
WT, but not Ifng-/-mice with MCMV resulted in downregulation of insulin receptor expression 
on transcriptional and protein amounts in muscle (Figure 5B-D; S5C, D). Likewise, infection 
with LCMV or Influenza A also resulted in down-regulation of Insr in muscle (Figure S5E). 
To investigate whether IFN- alone induces downregulation of Insr or whether this effect is 
only achieved in the context of viral infection, we injected IFN- daily in the m. sartorius of 
NCD or HFD primed mice. We observed that IFN-γ injection alone was able to cause 
upregulation of MHC II, a bona fide downstream target of IFNγR signaling, on muscle tissue 
macrophages (Figure S5F) and downregulation of Insr transcript in muscle but not in the liver 
(Figure 5E, S5G).  
Since MCMV infection has a long lasting negative effect on insulin sensitivity, at least 
in pre-diabetic mice, we wanted to elucidate whether 3 weeks p.i. Insr is still downregulated in 
muscle. We observed that transcription of Insr in muscle of HFD primed MCMV infected mice 
are still down-regulated at this time point (Figure 5F).  
Taken together, these results suggest that infection-induced IFN- drives IR in skeletal 
muscles through downregulation of the insulin receptor, resulting in GI in pre-diabetic animals. 
 
 
 
Infection-induced insulin resistance promotes antiviral CD8+ T cell responses 
Finally, we questioned the physiological relevance of IFN--induced IR. In lean 
animals, infection did not induce hyperglycemia, excluding increased nutrient availability as a 
cause. However, viral infection did cause hyperinsulinemia. Since insulin receptor and CD28 
signaling both converge on PI3K (Frauwirth et al., 2002), we hypothesized that insulin may 
directly provide co-stimulation for CD8+ T cells. We observed that CD8+ T cells expressed 
both Insr and Irs2, but not Irs1 (Figure 6A). Indeed, stimulation of primed CD8+ T cells with 
insulin rapidly induced phosphorylation of S6 kinase (Figure 6B), a downstream target of 
insulin-signaling. Next, we stimulated OT-1 CD8+ T cells in vitro with SIINFEKL peptides 
and/or CD28 antibodies in the presence or absence of insulin. Proliferation and viability were 
not affected by insulin (Figure S6A, B). In contrast, cytokine and Granzyme B production 
were enhanced by insulin, especially upon CD28 co-stimulation (Figure 6C).  
To confirm these findings in vivo in an obesity-independent model of hyperinsulinemia, 
lean mice were injected daily with basal (long-acting) insulin. Unlike short-working insulin 
used in ITT, basal insulin was slowly released in the blood stream and caused a continuous 
state of hyperinsulinemia. Basal insulin-treated animals were infected with MCMV and CD8+ 
T cell responses were analyzed after seven days. We observed that hyperinsulinemia promoted 
effector cell formation and cytokine production of virus-specific CD8+ T cells (Figure 7A, B). 
To test the importance of insulin on CD8+ T cell priming in a second model, we 
generated Ins2cre iDTR mice which allow elimination of insulin-producing pancreatic beta cells 
by injection of diphtheria toxin (DT). DT-treatment of Ins2cre iDTR abrogated their ability to 
produce insulin in response to a glucose bolus (Figure S7A, B, C), but did not result in overt 
morbidity at least one week after treatment. DT-treated Ins2cre iDTR or iDTR littermates were 
infected with MCMV and CD8+ T cell responses were analyzed one week later. DT-treatment 
caused reduction in the number of virus-specific CD8+ T cells upon MCMV infection and 
impaired their cytokine production (Figure 7C, D). Finally, after MCMV infection, DT-treated 
Ins2cre iDTR mice had reduced capacity to kill viral peptide-pulsed target cells (Figure 7E). To 
confirm that virus-induced muscle IR was responsible for the enhanced CD8+ T cell response 
we infected Ifngr1Myo mice and littermate controls with MCMV and analyzed CD8+ T cell 
responses one week later. Prevention of skeletal muscle IR caused reduction in the number 
KLRG1+ virus-specific CD8+ T cells (Figure 7F). Moreover, CD8+ T cells showed impaired 
cytokine production upon in vitro re-stimulation (Figure 7G). Thus, we have identified insulin 
as a molecule which promotes antiviral-effector CD8+ T cell responses.  
 
DISCUSSION 
Our research has addressed the question how viral infection contributes to development 
of DM2. We found that the activated immune system drove systemic IR in response to infection 
with various viruses, but not GI due to compensatory insulin output by the pancreas. In case of 
pre-existing metabolic dysfunction caused by DIO, compensatory mechanisms were 
overloaded and long-term loss of glycemic control ensued. We discovered that virally-induced 
IFN- directly and specifically targeted skeletal muscle to downregulate the insulin receptor 
and promoted compensatory hyperinsulinemia to boost the CD8+ T cell-mediated antiviral 
immune response. Thus, here we have identified a physiological feed-back mechanism between 
the immune and endocrine systems which operates in viral infection and we demonstrate that 
this mechanism represents an “Achilles heel” for deregulation of glycemic control in pre-
diabetic obese subjects. 
Current opinion in the field holds that IR is a derailed physiological response to 
systemic inflammation that aims to increase the systemic glucose set point to ensure optimal 
nutrient availability for activated immune cells (Kotas and Medzhitov, 2015). Indeed, extreme 
conditions, such as severe trauma or sepsis are able to induce hyperglycemia (Dungan et al., 
2009). Chronic injection of high-doses of LPS, a mouse model for severe sepsis (Doi et al., 
2009), is shown to induce hepatic insulin resistance and increase FPG through modification of 
the mevalonate pathway (Okin and Medzhitov, 2016). However, this so-called stress 
hyperglycaemia is only observed in critically ill patients (Dungan et al., 2009), and not 
following common infections such as we have investigated. Activated CD8+ T cells 
dramatically increase their requirement for glucose to satisfy needs for growth, proliferation 
and effector function (Maciver et al., 2008). Nevertheless, glucose uptake rather than glucose 
availability has shown to be the rate limiting step for effector CD8+ T cell function (Jacobs et 
al., 2008). Indeed, even at glucose concentrations that were tenfold lower than those normally 
observed during homeostasis, maximal CD8+ T cell effector function was achieved in the 
presence of sufficient co-stimulation (Jacobs et al., 2008). This seems at odds with the 
observation that starvation promotes lethality upon influenza infection of mice, which could be 
prevented by oral glucose gavage (Wang et al., 2016). However, caloric supplementation 
during viral infection does not induce loss of glycemic control (Wang et al., 2016). Our findings 
suggest that glucose administration during infection promotes immune responses indirectly by 
increasing systemic insulin concentrations.  Indeed, when we abrogated insulin production in 
mice, we observed reduced CD8+ T cell responsiveness, despite a state of systemic 
hyperglycemia.  
CD28 provides one of the strongest co-stimulatory signals for activation of CD8+ T 
cells through the activation of several signaling cascades, including the  PI3K pathway (Rudd 
et al., 2009). The insulin receptor exclusively signals through PI3K, thus sharing a major 
signaling cascade with CD28. Indeed, we found that insulin stimulation of CD8+ T cells during 
priming enhanced the costimulatory effects of CD28 and functioned as a pro-inflammatory 
cytokine. Immune cell-mediated increase of insulin availability at the time of CD8+ T cells 
priming, therefore benefits the immune response. However, immune-mediated adjustment of 
insulin production comes at a risk of inducing loss of glucose homeostasis and should therefore 
be carefully regulated. For example, if IFN- would directly stimulate pancreatic insulin 
production, it would induce potentially lethal hypoglycemia. Similarly, induction of IR in liver 
or VAT would result in an increase of FPG or circulating free fatty acids respectively (Karpe 
et al., 2011; Leto and Saltiel, 2012; Meshkani and Adeli, 2009). By targeting insulin sensitivity 
of muscle, increased insulin production by the pancreas both boosts the antiviral immune 
response, whilst ensuring blood glucose homeostasis. Muscle IR could cause reduced motility, 
but this is in fact a desirable behavior upon infection (Wang et al., 2016). Recently, it has been 
shown that under homeostatic conditions macrophage-derived IL-1 can promote insulin 
secretion which stimulates glucose uptake in immune cells (Dror et al., 2017). Our findings 
indicate that IL-1β does not reduce systemic glucose uptake following infection. However, 
neutralization of IL-1β resulted in enhanced glucose intolerance following infection, 
suggesting that immune-endocrine interactions operate at multiple levels to increase systemic 
insulin concentration.  
The role of obesity-induced visceral adipose tissue inflammation in development of IR 
has been well described. Adipocyte hypertrophy promotes accumulation of pro-inflammatory 
cells with a Th1 cell-signature, such as CD8+ T cells and M1 macrophages. Cytokines such as 
TNF, IL-6 and IL-1β produced by these cells leak into circulation and induce insulin resistance 
(Johnson et al., 2012). We and others have shown that NK cell derived IFN-γ promotes 
development of IR indirectly by driving conversion of adipose tissue macrophages (ATMs) 
towards an M1 phenotype (O'Rourke et al., 2012; Wensveen et al., 2015a). Infection-induced 
IR appears to operate independently of VAT. Moreover, we have demonstrated in vivo that 
IFN- is able to induce IR directly in non-immune cells. In vitro, IFN- had been shown to 
cause IR in 3T3-L1 adipocytes and myoblast by inhibiting insulin receptor signaling through 
induction of suppressor of cytokine signaling (SOCS) molecules (Grzelkowska-Kowalczyk 
and Wieteska-Skrzeczynska, 2009; McGillicuddy et al., 2009; Wada et al., 2011).  We show 
that in vivo IFN- specifically reduced glucose uptake in skeletal muscle by downregulation of 
the insulin receptor. 
DM2 affects almost half a billion of people worldwide with tens of millions more at 
risk of developing this disease (American Diabetes, 2018). In this study we showed that viral 
infection was a hyperglycemia-inducing “event” that was able to drive rapid transition from 
pre-diabetes to diabetes. Infectious diseases such as cytomegalovirus and influenza, for which 
we show that they cause IR in humans and mice, affect most of the human population 
(Colugnati et al., 2007). Prospective studies show that IR develops years to decades before 
onset of DM2. Increased  cell output of insulin compensates IR, resulting only in a marginal 
increase of FPG and 2HG (Tabak et al., 2009). When insulin resistance reaches a level that 
cannot be compensated anymore by increased insulin production of the pancreas, blood glucose 
values rapidly rise and DM2 ensues. We found that infection-induced IR was able to push 
animals beyond this threshold. However, the metabolic state of the subject (i.e. is hepatic IR 
established), as well as the nature and intensity of the infection appear to be crucial for 
determining whether the effect of the infection will be transient or permanent. Our results 
therefore have direct implications for the way health care specialists should approach infections 
or vaccination strategies in patients with pre-diabetes, since prevention of DM2 might be most 
effective at the time of this transition (Mason et al., 2007). Our findings indicate that, in 
addition to well established criteria such as obesity, hypertension and high triglyceride 
concentrations in circulation, viral infection should be considered as an important risk factor 
for development of DM2, especially in patients with prediabetes (American Diabetes, 2018). 
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Figure 1. Viral infection induces IR, but GI only after HFD-priming. Patients with 
respiratory infection were segregated in two groups (normal weight: BMI <25 (n=17), 
overweight: BMI>25 (n=14)) and analyzed at time of diagnosis and after 3 months for (A) FPI 
(B) FPG and (C) HOMA-IR index. (D) MCMV titters (PFU) in indicated tissues of B6 mice 
at day 4, 7 and 10 p.i. are shown. LD=limit of detection. (E) B6 mice were mock-infected or 
infected with MCMV and analyzed 7 days later by ITT. (F) B6 mice were mock-infected or 
infected with MCMV and analyzed 5 days later by hyperinsulinemic-euglycemic clamp. 
Glucose infusion rate (GIR) is shown. n=5. (G-H) B6 mice were mock-infected or infected 
with MCMV and analyzed 7 days later by (G) GTT and (H) serum insulin concentrations after 
glucose challenge upon overnight fasting were measured. In addition, area under curve is 
shown. (I-K) Mice were placed on NCD or HFD for 6 weeks (‘pre-diabetic’ mice) before 
infection with MCMV or PBS. One week later, they were subjected to (I) ITT or (J) GTT. (K) 
GTT was also performed three weeks after infection. (L-P) Mice were infected with MCMV 
simultaneously with the start of HFD. Eight weeks p.i. mice were subjected to (L) GTT and 
(M) ITT. In addition, (N), sizes of juxtamedullary glomeruli were determined 16 weeks p.i. 
(n=5; 72 glomeruli per animal). 24 weeks p.i. (O) PAS staining of kidney sections was 
performed. (Green arrow) expansion of mesangial matrix and (yellow arrow) increased 
Bowman capsule size or (P) thickness of basement membrane are shown. (Q) MCMV infected 
pre-diabetic mice were treated daily with ganciclovir starting 24 h p.i. or with PBS. After seven 
days, mice were subjected to GTT. The experiment in Figure F was performed once. For all 
other experiments, a representative of three experiments is shown. For (D-Q) five mice were 
used in each group. Indicated are means ± s.e.m. and statistical significances at * p<0.05, ** 
p<0.01, ***p<0,001 by (A-C, E-H) Student`s t test or (I-Q) ANOVA followed by Bonferroni 
post-testing. p.i. - post infection. See also Figure S1.  
 
 
 
 
 
 
Figure 2. Infection-induced IFN- promotes development of GI and IR in pre-diabetic 
mice. (A-F) Mice were fed for 6 weeks with indicated diets, followed by MCMV infection. 
Control mice were treated with PBS. (A) Seven days p.i., mice were fasted overnight and 
challenged with glucose. Insulin concentartions were determined in serum by ELISA. (B) 
Insulinogenic index during GTT. (C, D) Infected pre-diabetic or NCD-fed mice were injected 
every three days with neutralizing mAbs to IFN- or with isotype matched irrelevant mAbs 
starting 24 h before infection. (C) GTT and (D) ITT were performed on day 7 after infection. 
Infected pre-diabetic mice injected with (E) CD4- or CD8-depleting, or (F) NK cell depleting 
antibodies. Control animals were treated with isotype matched irrelevant mAbs. GTT was 
performed on day 7 p.i.. (G) B6 or Ifng-/- mice were infected with MCMV.  Ifng-/- mice were 
transferred with NK cells or PBS one day before infection and three days later. Five days p.i. 
mice were subjected to ITT. For (A-G) representative of three experiments is shown. For (A-
G) five mice were used in each group.  Indicated are means ± s.e.m. and statistical significances 
at * p<0.05, ** p<0.01, ***p<0,001 by ANOVA followed by Bonferroni post-testing. p.i. - 
post infection. See also Figure S2. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Infection-induced IR and GI is mediated independently of macrophages, 
adipocytes and hepatocytes. (A) Serum IFN- concentrations were determined by ELISA at 
different time points after infection of mice primed with HFD or NCD for 6 weeks. (B) Pre-
diabetic mice were MCMV or mock infected and treated with neutralizing mAbs to IFN- every 
three days starting one day before or 7 days p.i. Fourteen days p.i. mice were subjected to GTT. 
(C, D) Pre-diabetic Ifngr1ΔMac mice and Ifngr1lox/flox littermates were injected with MCMV or 
PBS. Seven days p.i. mice were subjected to (C) ITT or (D) GTT. (E) Mice either underwent 
sham operation or surgical excision of periepididymal fat pad (VATectomy). Two weeks after 
surgery, mice were infected with MCMV and placed on HFD. GTT was performed after 8 
weeks. (F, G) Pre-diabetic Ifngr1Adi mice and Ifngr1flox/flox littermates were injected with 
MCMV or PBS. Five and seven days after infection mice were subjected to (F) ITT or (G) 
GTT respectively. (H-J) Mice were fed for 6 weeks with indicated diets, followed by MCMV 
or PBS injection. (H) FPG was determined seven days after infection. (I) PTT was performed 
on day seven after infection. (J) Seven days p.i., mice were fasted overnight, followed by 
injection with insulin. After 30 minutes liver samples were isolated and pan-Akt and pAkt 
amounts were determined by Immuno blotting. (K) B6 mice were mock-infected or infected 
with MCMV and endogenous glucose production was analyzed 5 days later during hyper-
insulinemic-euglycemic clamp.  (H) Pooled data of 12 experiments (n=60) is shown (analyzed 
by ANOVA with Bonferroni post-testing). The experiment in Figure 3K was performed once. 
Other graphs show one of two or more experiments with similar results. For (A-G) and (I-K) 
five mice were used in each group. Indicated are means ± s.e.m. and statistical significances at 
* p<0.05, ** p<0.01, ***p<0,001 by student`s t test or ANOVA followed by Bonferroni post-
testing. p.i. - post infection. See also Figure S3. 
 
 
 
 
 
 
Figure 4. IFN- induces IR specifically in the skeletal muscle. (A, B) B6 and Ifng-/- mice 
were NCD or HFD-fed for 6 weeks, followed by MCMV infection. After seven days mice were 
fasted overnight, followed by injection with insulin. After 30 minutes skeletal muscle samples 
were isolated and pan-Akt and pAkt amounts were determined by Immuno blotting. (C) Pre-
diabetic Ifngr1Myo mice and Ifngr1lox/flox littermates were injected with MCMV or PBS. Five 
and seven days p.i., mice were subjected to ITT and GTT. (D) Glucose uptake into VAT and 
skeletal muscle during hyperinsulinemic-euglycemic clamping 5 days after MCMV infection 
of NCD fed mice. The experiment in Figure D was performed once. In (A, B) density 
quantification plot shows pooled data from two independent experiments. For C a 
representative of three experiments is shown. For (A-D) five mice per experiment were used 
in each group.  Indicated are means ± s.e.m. and statistical significances at * p<0.05, ** p<0.01, 
***p<0,001 by (D) Student`s t test or (A-C) ANOVA followed by Bonferroni post-testing. p.i. 
- post infection. See also Figure S4. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. IFN induces IR in the skeletal muscle through downregulation of the insulin 
receptor.  (A) Pre-diabetic or NCD fed mice were infected with MCMV or left untreated. On 
day 7 after infection, Insr transcripts were determined in muscle and liver by qPCR. Expression 
was normalized to Hprt. (B) Skeletal muscle samples were isolated 7 days after MCMV 
infection of pre-diabetic mice, and protein expression of insulin receptor was determined by 
immuno blot. (C, D) Ifng-/- mice were MCMV or mock infected and after five days skeletal 
muscle samples were isolated and (C) Insr expression was determined by qPCR. Expression 
was normalized to Hprt. (D) Protein expression of the InsR were determined by Immuno blot. 
(E) Pre-diabetic or NCD fed mice were injected daily in one m. sartorius with mouse 
recombinant IFN- or PBS After 3 days, transcript of Insr were determined in m. sartorius. R 
(right)- site of injection; L (left) – collateral symmetric muscle. (F) Prediabetic or NCD fed 
mice were infected with MCMV. Three weeks p.i. Insr expression in muscle was determined 
by qPCR. Representative of two (E, F) or three (A-D) experiments is shown. For (A-F) at least 
four mice were used in each group.  Indicated are means ± s.e.m. and statistical significances 
at * p<0.05, ** p<0.01, ***p<0,001 by (A, E-F) ANOVA followed by Bonferroni post-testing 
or (B-D) Student`s t test. p.i. - post infection. See also Figure S5. InsR – protein expression. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Insulin promotes activation of CD8+ T cells (A) qPCR was used to quantify 
expression of Insr, Irs2 and Irs1 in purified OT-1 CD8+ T cells. Expression was normalized to 
Hprt.  (B) Purified OT-1 cells were stimulated with SIINFEKL (N4) peptide in the presence or 
absence of anti-CD28. After 2 days, cells were rested from stimuli for 3h, followed by 
stimulation with 1 IU/ml of insulin. Kinetics of S6 phosphorylation were determined by flow 
cytometry. Representative plot shows cells primed with N4 and αCD28 at 0 and 15min after 
insulin stimulation. (C) Purified OT-1 cells were stimulated with N4 peptide alone or in the 
presence of insulin and/or anti-CD28. After 48 h, cells were re-stimulated with N4 peptide and 
production of Granzyme B, IFN- and TNF was measured by flow cytometry. For (A-C) a 
representative of at least three experiments is shown. For (A-C) at least three samples were 
used in each group Indicated are means ± s.e.m. and statistical significances at * p<0.05, ** 
p<0.01, ***p<0,001 by (C) ANOVA followed by Bonferroni post-testing. See also Figure S6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7. Insulin promotes anti-viral CD8+ effector T cell responses. (A, B) B6 mice were 
infected with MCMV and treated daily with basal insulin or PBS. Seven days p.i. (A) effector 
cells (KLRG1+) specific for two MCMV epitopes were quantified in spleen. Histograms show 
representative plots. Gated on CD8+ tetramer+ cells. (B) Splenocytes were re-stimulated in vitro 
with indicated peptides and TNF production was analyzed by flow cytometry. (C-E) 
Ins2creRosaiDTR and RosaiDTR littermates were DT-treated and subsequently infected with 
MCMV. After seven days (C) absolute numbers of antigen-specific cells were determined in 
spleen. (D) Splenocytes were re-stimulated in vitro with viral peptides and cytokine production 
was analyzed by flow cytometry. (E) Mice were injected with splenocytes pulsed with control, 
m57 or m139 peptides, labelled with different CFSE concentrations. After 4h, specific killing 
was determined in spleen. (F, G) Ifngr1Myo mice and Ifngr1flox/flox littermates were infected 
with MCMV. After seven days (F) effector cells (KLRG1+) specific for two MCMV epitopes 
were quantified in spleen. In addition, (G) splenocytes were re-stimulated in vitro with two 
different viral peptides and production of the IFN- and TNF was analyzed with flow 
cytometry.  For (A-E) five mice and for (F-G) eight mice were used in each group.  
Representative of two or more experiments is shown.  Indicated are means ± s.e.m. and 
statistical significances at * p<0.05, ** p<0.01, ***p<0,001 by (A-G) Student`s t test. p.i. - 
post infection. See also Figure S7. 
 
 
 
 
 
 
 
 
 
 
 
 STAR METHODS 
CONTACT FOR REAGENT AND RESOURCE SHARING 
As Lead Contact, BP is responsible for all reagent and resource requests. Please contact BP at 
bojan.polic@medri.uniri.hr with requests and inquiries. 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
 
Mouse strains  
Male mice were strictly age- and sex-matched within experiments and handled in 
accordance with institutional and national guidelines. All mice were housed and bred under 
specific pathogen free condition at the animal facility of the Medical faculty, University of 
Rijeka. Wild type C57BL/6J (B6; strain 664), Ifng-/- (2287), Ifngr1flox/flox (25394), Adipoqcre 
(10803), Ckmcre (6475), Ins2cre (003573), Albcre (003574), Lyz2cre (4781), B6 Ly5.1 (2014) and 
OT-1 (3831) mice were obtained from the Jackson Laboratory. iDTR were a kind gift from 
prof. Ari Waisman, Mainz, Germany. All genetically modified animal models were generated 
on the C57BL/6J background or backcrossed at least ten times with C57BL/6J mice. Male mice 
(8-12 weeks old) were fed ad libitum either with NCD (SSNIFF) or with HFD in which 50% 
of calories was derived from animal fat (Bregi). All animal experiments were approved by the 
National Committee for welfare of animals. 
Viruses 
The bacterial artificial chromosome–derived murine cytomegalovirus (BAC-MCMV) strain 
pSM3fr-MCK-2fl clone 3.3 has previously been shown to be biologically equivalent to the 
MCMV Smith strain (VR-1399; ATCC) and is referred to as wild-type (WT) MCMV (Wagner 
et al., 2013). pSM3fr-MCK-2fl clone 3.3 and Δm157 (Hirche et al., 2017) were propagated on 
mouse embryonic fibroblasts (MEF). Animals were infected intravenously i.v. with 2x105 
PFU. Viral titers were determined on MEF by standard plaque assay. Lymphocytic 
choriomeningitis virus (LCMV) Armstrong strain (Armstrong E-350; ATCC) was propagated 
on baby mouse kidney cells according to standard protocol. Animals were infected 
intraperitoneally i.p. with 106 PFU. Influenza A strain A/PR/8/34 (ATCC) was generated in 
LLC-MK2 cells and TCID50 was determined in wild-type B6 mice. Mice were infected 
intranasally with 10 x TCID50 under ketamine/xylazine anesthesia. 
 
Glucose tolerance, insulin tolerance and pyruvate tolerance test 
For glucose tolerance (GTT) and insulin tolerance (ITT) tests mice were fasted for 6 h 
and then injected with 1g/kg of D-glucose (Sigma) i.p. or with 1 U/kg of human fast working 
insulin (Aspart, Novo Nordisk) dissolved in saline solution, respectively. In the end of ITT 
mice were injected i.p. with 1 g/kg of D-glucose (Sigma) to prevent consequence of the 
hypoglycemia. To measure pyruvate tolerance (PTT), mice were fasted for 16 h and then 
injected with 1 g/kg i.p. of pyruvate sodium solution (Sigma). Glucose was measured in blood 
from the v. saphena with an automated glucometer (SD Codefree). ITT is a standard metabolic 
test that is commonly used to assess sensitivity of the insulin receptor before and after insulin 
administration, while GTT measures glucose disposal after glucose challenge. These two tests 
are commonly used to detect impairments in glucose metabolism. 
 
Insulinogenic index 
To investigate the impact of the infection on insulin secretion we calculated insulinogenic 
index. Insulinogenic index is defined as a ratio between insulin areas and glucose areas under 
curve during GTT (Dalmas et al., 2017).  
 
Glucose clamp studies  
Hyperinsulinemic-euglycemic clamp studies were performed in freely moving mice as 
described (Wueest et al., 2010). Mice were anesthetized with isofluran and eye ointment was 
applied to both eyes. A catheter (MRE 025, Braintree Scientific, Braintree, MA, USA) was 
inserted into the left jugular vein and exteriorized at the neck. Two to three days after surgery, 
DMEM (control) or 2x105 PFU MCMV virus dissolved in DMEM was injected via catheter. 
Five days p.i., hyperinsulinemic-euglycemic clamp was performed. Insulin was infused at a 
constant rate (12 mU/kg*min) and steady state glucose infusion rate was calculated once 
glucose infusion reached a more or less constant rate for 15-20 min with blood glucose 
concentrations at 5-6 mmol/l. The glucose disposal rate was calculated by dividing the rate of 
[3-3H] glucose infusion by the plasma [3-3H] glucose specific activity. Endogenous glucose 
production during the clamp was calculated by subtracting the glucose infusion rate from the 
glucose disposal rate. In order to assess tissue specific glucose uptake, a bolus (10 Ci) of 2-
[1-14C] deoxyglucose was administered via catheter at the end of the steady state period. Blood 
was sampled 2, 15, 25 and 35 min after bolus delivery. Area under the curve of disappearing 
plasma 2-[1-14C] deoxyglucose was used together with tissue-concentration of phosphorylated 
2-[1-14C] deoxyglucose to calculate glucose uptake. 
 
ELISA 
To analyze serum insulin concentrations, animals were fasted overnight and injected 
with 1 g/kg of D-glucose. Blood was isolated from the v. saphena using heparin coated plastics. 
Insulin was measured in plasma using the mouse ultrasensitive insulin ELISA kit (Alpco). IFN-
 concentrations were measured with the mouse IFN-gamma Platinum ELISA (eBioscience) 
according to manufacturer`s protocol. Plates were analyzed using a Mithras LB940 ELISA 
plate reader (Berthold technologies).  
 
ImmunoBlot 
After overnight fasting, mice were injected with 1 U/kg of human fast working insulin 
(Aspart, Novo Nordisk). After 30 min VAT, liver and muscle were isolated and snap-frozen in 
liquid nitrogen. Samples were lysed in Triton lysis buffer (50 mM HEPES, 1% Triton X-100, 
10 mM EDTA, 0.1% SDS, 50 mM NaCl, complete ULTRA Tablets, Mini, Easypack (Protease 
inhibitor cocktail tablets) (Roche) and PhosStop EASYpack (Phosphatase inhibitor cocktail 
tablets) (Roche) in a tissue homogenizer. Protein contents were determined by the Pierce BCA 
Protein Assay Kit (Thermo Fisher Scientific) and equal amounts of total lysate were analyzed 
by 12% SDS-polyacrylamide gel electrophoresis. Proteins were transferred to Immobilon-P 
and incubated with blocking buffer (Tris buffered saline/Tween-20) containing 2% low-fat 
milk for 1 h before incubating with an antibody against the insulin receptor, p-Akt (Ser473) and 
pan-Akt from Cell Signaling. Bands were visualized with ECL Prime Immuno Blotting 
Detection Reagent (GE Healthcare) using ImageQuant LAS 4000mini (GE Healthcare, Life 
Science). Density of bands was calculated relative to pan-Akt using ImageJ software.  
 
Quantitative PCR 
Muscle (m. sartorius) or liver pieces were lysed in Trizol with a tissue homogenizer. 
RNA was isolated via the Trizol method (Invitrogen), and cDNA was generated with a reverse 
transcriptase core kit (Eurogentec). The expression of mRNA was examined by quantitative 
PCR with a 7500 Fast Real Time PCR machine (ABI). Taqman assays were used to quantify 
the expression of Ifng (Mm00485148_m1) and Socs3 (Mm00545913_s1). The relative mRNA 
expression was normalized by quantification of -actin (Actb, Mm00607939_s1) RNA in each 
sample.  For expression of Insr, Socs1, Irs1 and Irs2 qPCR was performed by monitoring in 
real time the increase in fluorescence of the SYBR Green dye (Eurogentec) according to 
manufacturer`s protocol. Primer sequences were as follows: Insr forward 5′-
TTTGTCATGGATGGAGGCTA-3′ and reverse 5′ CCTCATCTTGGGGTTGAACT-3', Socs1 
forward 5’- GATTCTGCGTGCCGCTCT-3’ and reverse 5’- 
TGCGTGCTACCATCCTACTC-3', Irs1 forward 5'- CTCTACACCCGAGACGAACAC-3' 
and reverse 5'- TGGGCCTTTGCCCGATTATG-3’, Irs2 forward 5’-
CGAGTCAATAGCGGAGACCC-3’ and reverse 5’- CCCCTGAGACCCTACGGTAA-
3’.The relative mRNA expression was normalized by quantification of Hrts (forward 5’-
CACAGGACTAGAACACCTGC-3' and reverse 5'- GCTGGTGAAAAGGACCTCT-3'). 
 
Antibodies and Flow cytometry 
Antibodies for in vivo applications (CD4 (YTS191.1.2), CD8 (YTS169.4.2), NK1.1 
(PK136), IFN- (R4-6A2), Il-1 (BE0246) and isotype controls were produced by our in-house 
facility or purchased from BioXcell. For flow cytometry, single-cell suspensions of spleen were 
prepared according to standard protocols. Flow cytometric analysis were performed by using 
anti-mouse mouse CD4 (GK1.5), CD3 (145-2C11), CD8β (53-6.7), CD62L (MEL-14), CD127 
(A7R34), KLRG1 (2F1), NK1.1 (PK136), CD11b (M1/70), CD11c (N418), CD86 (GL1), GR1 
(RB6 8C5), F4/80 (BM8), TNF (MP6-XT22), IFN- (XMG1.2) and granzyme B (NGZB) from 
eBioscience, preceded by blocking of Fc receptors using 2.4G2 antibodies (in house generated). 
To measure cytokine production, cells were stimulated with 1 μg of MCMV peptides M57 
(SCLEFWQRV) or m139 (TVYGFCLL) or with SIINFEKL (N4) peptide for 4 h in the 
presence of Brefeldin A (10 μg/ml; eBioscience). MHC class I tetramers were provided by A. 
ten Brinke (Amsterdam, The Netherlands). For intracellular staining, permeabilization and 
fixation of cells was done with the Fix/Perm kit (BD Biosciences). All data were acquired using 
a FACSVerse (BD Biosciences) and analyzed using FlowJo software (Tree Star). 
 
Human data 
Patients in the age group of 18-70yrs, diagnosed with acute respiratory infection 
(Influenza, Human respiratory syncytial virus (HRSV)) were recruited from the Dept. of 
Infectology at the Clinical Medical Center of Rijeka. Pneumonia was diagnosed with chest x-
ray. Influenza and HRSV were determined by PCR on RNA isolated from nasopharyngeal 
swabs by our clinical diagnostics laboratory. Patients suffering from kidney failure, chronic 
inflammatory or autoimmune diseases or patients with a previous history of glucose intolerance 
or diabetes (anamnesis and HbA1c) were excluded from this study. Whole blood was drawn 
on two-time points: acute infection (days 1-7 from the onset of symptoms) and post illness 
period (90-100 days after first analysis). Insulin concentrations were measured in plasma by 
electro-chemiluminescence immunoassay (ECLIA) on a Cobas E411 analyzator (Roche, 
Switzerland) and HbA1c were measured in full blood using a turbidimetric inhibition 
immunoassay (TINIA) on a Cobas 501 analyzator (Roche, Switzerland). Body mass index of 
every patient was determined at first analysis. Fasting insulin and glucose concentrations were 
used to calculate HOMA-IR as described (Matthews et al., 1985) . An informed consent was 
obtained from patients after the nature and possible consequences of the studies were 
explained. This study was approved by the University of Rijeka Medical Faculty Ethics 
Committee before initiation.  
 
Methods performed in vivo 
VATectomy was done as described (Wensveen et al., 2015a). In brief, mice either 
underwent sham operation or had periepididymal fat pad removed (VATectomy). Two weeks 
after surgery, mice were placed on NCD or HFD and infected with MCMV or left untreated. 
For adoptive transfer, NK cells were isolated and purified using biotinylated DX5 antibodies, 
streptavidin-coated beads and magnetic cell sorting (Miltenyi) from spleen and blood. Purity 
was determined by flow cytometry. 5x106 NK cells were transferred i.v. in to Ifng-/- mice one 
day before infection and three days after initial transfer. For induction of liver damage using 
CCL4, mice were treated twice a week with 200 l of a 10% solution of CCL4 diluted in mineral 
oil. To induce liver damage with paracetamol, animals received 100 mg/kg of paracetamol 
dissolved in PBS twice per week. For depletion of macrophages, mice were injected once 
weekly with 45 mg/kg of clodronate liposomes or with unloaded liposomes as a control starting 
one day before infection. Poly I:C was injected i.p. twice per week at 200 g per mouse. 
MCC950 (Cayman Chemical) was administrated i.p. every second day at doses of 20 mg/kg. 
Poly I:C and MCC950 treatments were started one day before infection with MCMV. For 
depletion of pancreatic -cells in Ins2creiDTR mice, 25 ng/g of Diphteria Toxin (DT, Merck) 
was injected i.p. 48 h and 24 h before infection. Hyperinsulinemia in mice was achieved with 
daily i.p. injection of 10 IU/kg of basal insulin (Degludek, Novo Nordisk), starting one day 
before infection with MCMV. For inhibition of viral replication, mice were injected i.p. once 
daily, starting one day post infection, with 40 mg/kg of ganciclovir (MCE), diluted in PBS. 104 
UI of mouse recombinant IFN- was injected daily in to m. sartorius. In vivo killer assay was 
done as described (Durward et al., 2010). Briefly, DT-treated Ins2creiDTR and iDTR littermate 
controls were infected with MCMV. After seven days animals were injected i.v. with 5x106 
CD45.1 splenocytes. Before transfer splenocytes were pulsed for 1 h with 1 μg/ml M57 
(MCMV), M139 (MCMV) or PB1-F2 (Flu) peptides, washed and mixed in 1:1:1 ratio. Cells 
could be distinguished based on differential CFSE (Molecular Probes) labeling. 4 h after 
transfer, specific killing of MCMV-pulsed cells, relative to Flu-pulsed cells was determined in 
spleen using flow cytometry.  
 
Cell assays  
CD8+ OT-1 T cells were purified by magnetic cell separation (Miltenyi, Biotec). Cells 
were cultured in RPMI 1640 medium (PAN-Biotech), supplemented with 10% FCS (PAN-
Biotech) and 2-ME (Sigma-Aldrich). Cells were CFSE-labeled and stimulated in vitro with 1 
ng/ml of SIINFEKL (N4) peptide in presence or absence of 0.5 g/ml of αCD28 (37.51, 
eBioscience) and 1 U/ml of insulin (Aspart, Novo Nordisk). For proliferation, CFSE dilution 
was determined by flow cytometry after 72 h. For cytokine production, after 48 h of culture, 
cells were re-stimulated with 10 ng/ml N4 peptide in presence of Brefeldin A. After 4 h 
cytokines were measured by intracellular flow cytometry. For phosphorylation kinetics of S6, 
cells were stimulated with ng/ml N4 peptide in the presence or absence of 0.5 g/ml of CD28. 
After 2 days, cells were stimulated with 1 U/ml of fast working insulin insulin (Aspart, Novo 
Nordisk) for 0, 5, 15 and 30 min. Cells were fixed with 2% paraformaldehyde, permeabilized 
in 90% methanol, stained for pS6 (Cell signaling), visualized with anti-rabbit PE (eBioscience) 
and measured by flow cytometry.  
 
Histology 
Organs were fixed in 10% neutral buffered formalin and embedded in paraffin. For 
morphometric and pathohistological analyzes of kidney (glomeruli) section were stained with 
PAS. For PAS staining, the samples were incubated in 0.1% periodic acid for 10 min. The 
kidney sections were washed in running tap water for 1 min and immersed in Schiff’s reagent 
for 17 min. Subsequently, the sections were washed in tap water for 3 min, counterstained with 
Mayer’s hematoxylin for 2 min, washed in tap water for 3 min, and dehydrated in two changes 
of  96% alcohol. Finally, the sections were cleared in xylene and mounted with Entellan (Sigma 
Aldrich). Glomerular area was determined using the Cell^ B Soft Imaging System (Olympus). 
Three slides per animal and 24 glomeruli per each slide were analyzed. Analysis of diabetic 
nephropathy was performed on PAS-stained slides by a trained pathologist on blinded sections. 
For detection of liver fibrosis, liver sections were stained with Sirius red staining. First slides 
were baked at 60°C for 1 h and then taken through xylene and graded ethanols (100%, 95%, 
85%, 75%, 60%, 50%) into distilled water. Slides were then stained overnight (minimum 14 
h) in saturated picric acid with 0.1% Sirius Red F3BA (Aldrich Chemicals). The next morning 
slides were removed, washed in 0.01 N hydrochloric acid for 2 min, and rapidly dehydrated 
through graded alcohols starting at 70%, then to xylene, and finally cover slipped.  
 
Statistical analyses 
Data are presented as mean ± SEM. Statistical significance was determined by either 
two-tailed unpaired Student’s t test, Mann Whitney (U) test or one-way ANOVA with 
Bonferroni correction using Graph Pad Prism 5. A value of p>0.05 was deemed not statistically 
significant (ns); *p<0.05, **p<0.01 and ***p<0.001. 
 
KEY RESOURCES TABLE 
 
REAGENT or RESOURCE SOURCE IDENTIFIE
R Antibodies 
Rat anti mouse CD4 monoclonal antibody (clone GK1.5) eBioscience Cat. # 
14-0041 
Armenian hamster anti mouse CD3e monoclonal antibody 
(clone 145-2C11) 
eBioscience Cat. #  
11-0031 
Rat anti mouse CD11b monoclonal antibody (clone M1/70) eBioscience Cat. # 
25-0112 
Rat anti mouse CD127 monoclonal antibody (clone A7R34) eBioscience Cat. # 
12-1271 
Mouse anti mouse CD62L monoclonal antibody (clone MEL-
14) 
eBioscience Cat. # 
11-0621-82 
Syrian hamster anti mouse KLRG1 monoclonal antibody 
(clone 2F1) 
eBioscience Cat. #  
11-5893-82 
Mouse anti mouse NK1.1 monoclonal antibody (clone 
PK136) 
eBioscience Cat. # 
11-5941-82 
Armenian hamster anti mouse CD11c monoclonal antibody 
(clone N418) 
eBioscience Cat. # 
11-0114-82 
Rat anti mouse CD86 monoclonal antibody (clone GL1) eBioscience Cat. #  
17-0862-82 
Rat anti mouse GR1 monoclonal antibody (clone RB68C5) eBioscience Cat. #  
11-5931-82 
Rat anti mouse F4/80 monoclonal antibody (clone BM8) eBioscience Cat. #  
11-4801-82 
Rat anti mouse granzyme B monoclonal antibody (clone 
NGZB) 
eBioscience Cat. #  
11-8898-82 
Rat anti mouse IFN-γ monoclonal antibody (Clone: XMG1.2) eBioscience Cat. #  
17-7311-82 
Rat anti mouse TNF monoclonal antibody (Clone: MP6-
XT22) 
eBioscience Cat. #  
11-7321-82 
Mouse monoclonal anti-mouse β-aktin (AC-15) Santa Cruz 
Biotechnology 
sc-69879 
Syrian hamster anti mouse CD28 (37.51) monoclonal 
antibody 
eBioscience Cat. # 13-
0281-82 
Rat anti mouse CD8 monoclonal antibody (Clone: 53-6.7) eBioscience Cat. # 45-
0081-80 
Rat IgG2a kappa Isotype control eBioscience Cat. # 12-
4321-82 
Mouse IgG1 kappa Isotype control eBioscience Cat. # 45-
4714-80 
Rat IgG2a kappa Isotype control eBioscience Cat. # 25-
4321-81 
Mouse anti mouse CD49b monoclonal antibody (biotin) 
(Clone: DX5) 
eBioscience Cat. # 13-
5971-82 
Fixable Viability Dye eFluor™ 780 eBioscience Cat. #  65-
0865-14 
Rabbit anti mouse pS6 (Clone: D57.2.2) Cell signaling Cat. # 4858S 
Rabbit anti mouse Insulin receptor (Clone: 4B8) Cell signaling Cat. # 3025S 
Rabbit anti mouse p-Akt (Ser473) (Clone: D9E) Cell signaling Cat. # 4060S 
Rabbit anti mouse Pan-AKT (Clone:11E7) Cell signaling Cat. # 4685S 
CD4 (Clone: YTS191.1.2) In house produced  
CD8 (Clone: YTS169.4.2) In house produced  
NK1.1 (Clone PK136) BioXCell Cat. # 
BP0036 
IL-1 (Clone B122) BioXCell Cat. # 
BE0246 
IFN- (Clone R4-6A2) BioXCell Cat. # 
BE0054 
Mouse recombinant IFN- Preprotech Cat. # 315-
05 
Bacterial and Virus Strains   
MCMV strain pSM3fr-MCK-2fl clone 3.3 In-house produced https://www
.ncbi.nlm.ni
h.gov/pubm
ed/2393548
3 
MCMV strain Δm157 In-house produced https://www
.ncbi.nlm.ni
h.gov/pubm
ed/2861471
9 
LCMV Armstrong strain (Armstrong E-350; American Type 
Culture Collection) 
ATCC VR-1271™ 
Influenza A strain A/PR/8/34 ATCC VR-1469 
Biological Samples   
N/A   
Chemicals, Peptides, and Recombinant Proteins   
Brefeldin A eBioscience Cat. 00-
4506-51 
CFSE Sigma CAS 
Number: 
150347-59-
4 
M57, SCLEFWQRV; Genscript Custom 
m139, TVYGFCLL; Genscript Custom 
SIINFEKL - N4 Genscript Custom 
Poly I:C Sigma-Aldrich CAS 
Number: 
42424-50-0 
Glucose Sigma-Aldrich CAS 
Number: 50-
99-7 
2-[1-14C] deoxyglucose PerkinElmer NEC495A0
50UC 
Insulin (fast working insulin) Novo Nordisk  
Insulin (basal) Novo Nordisk  
Pyruvate sodium solution Sigma-Aldrich Cas 
Number: 
113-24-6 
CCL4 Sigma-Aldrich CAS 
Number: 56-
23-5 
Mineral oil Sigma-Aldrich CAS 
Number: 
8042-47-5 
Paracetamol Sigma-Aldrich CAS 
Number: 
103-90-2 
MCC950 Cayman Chemical CAS 
Number 
210826-40-
7 
Diphteria Toxin Merck Cat. # 
322326 
Sirius Red F3BA Aldrich Chemicals CAS 
Number 
2610-10-8 
Schiff’s Sigma Aldrich CAS 
Number 
3952016 
Mayer’s hematoxylin Sigma Aldrich MDL 
Number 
MFCD0007
8111 
Ganciclovir Sigma Aldrich CAS 
Number 
824410-32-
0 
Clodronate liposomes Liposoma https://clodr
onateliposo
mes.com/sh
op/ 
Complete ULTRA Tablets, Mini, Easy pack (Protease 
inhibitor cocktail tablets) 
Roche Cat. # 
0589279100
1 
PhosStop EASYpack (Phosphatase inhibitor cocktail tablets) Roche Cat. # 
PHOSS-RO 
Ketamine hydrochloride Sigma Aldrich CAS 
Number 
1867-66-9 
Xylazine Sigma Aldrich CAS 
Number 
7361-61-7 
SYBR Green dye Eurogentec Cat. #  
05-SN2X-
03T 
Critical Commercial Assays   
Fixation/Permeabilization Solution Kit BD Biosciences Cat. # 
554714 
CD8a (Ly2) microbeads mouse Miltenyi Biotec Cat. #  
130-049-
401 
Streptavidin MicroBeades Miltenyi Biotec Cat. # 130-
048-101 
LS columns Miltenyi Biotec Cat. #  
130-042-
401 
TRIzol Invitrogen Cat. # 
15596026 
SuperScript II cDNA synthesis kit Invitrogen Cat. # 18064 
Reverse Transcriptase Core Kit 300 Eurogentec Cat. # 05-
RTCK-03 
Taqman assays Ifng (Mm00485148_m1) Thermo Fisher 
Scientific 
Cat. # 
4331182 
Taqman assays Socs3 (Mm00545913_s1). Thermo Fisher 
Scientific 
Cat. # 
4331182 
Pierce BCA Protein Asay Kit Thermo Fisher 
Scientific 
Cat. # 23225 
 
Mouse ultrasensitive insulin ELISA kit Alpco Cat. # 80-
INSMSU-
E01 
Mouse IFN-gamma Platinum ELISA Thermo Fisher 
Scientific 
Cat. # 
BMS609 
ECL Prime Western Blotting Detection Reagent GE Healtcare RPN2232 
Catheter (MRE 025) Braintree Scientific MRE025 10
00 FT 
Deposited Data   
N/A   
Experimental Models: Cell Lines   
N/A   
Experimental Models: Organisms/Strains   
C57BL/6 (B6; line 664) Jackson Laboratories JAX: 
000664 
Ifng-/- Jackson Laboratories JAX: 
00287 
Ifngr1flox/flox Jackson Laboratories JAX: 
025394 
Adipoqcre Jackson Laboratories JAX: 
010803 
Ckmcre Jackson Laboratories JAX: 
006475 
Ins2cre Jackson Laboratories JAX: 
003573 
Albcre Jackson Laboratories JAX: 
003574 
Lyz2cre Jackson Laboratories JAX: 
004781 
B6Ly5.1 Jackson Laboratories JAX: 
002014 
OT-1 Jackson Laboratories JAX: 
003831 
iDTR Prof. Ari Waisman, 
Mainz, Germany 
N/A 
Primers   
Insr fwd 5′-TTTGTCATGGATGGAGGCTA-3′ Metabion Custom 
Insr rev5′ CCTCATCTTGGGGTTGAACT-3' Metabion Custom 
Socs1 fwd 5’- GATTCTGCGTGCCGCTCT-3’ Metabion Custom 
Socs1 rev 5’- TGCGTGCTACCATCCTACTC-3' Metabion Custom 
Irs1 fwd 5'- CTCTACACCCGAGACGAACAC-3' Metabion Custom 
Irs1 rev 5'- TGGGCCTTTGCCCGATTATG-3 Metabion Custom 
Irs2 fwd 5’-CGAGTCAATAGCGGAGACCC-3’ Metabion Custom 
Irs2 rev 5’- CCCCTGAGACCCTACGGTAA-3 Metabion Custom 
Hprt fwd: 5’-CACAGGACTAGAACACCTGC-3' Metabion Custom 
Hprt rev: 5'- GCTGGTGAAAAGGACCTCT-3' Metabion Custom 
Recombinant DNA   
N/A   
Software and Algorithms   
Flow Jo FLOWJO, LLC 
(Tree Star) 
 
GraphPad Prism GraphPad Software  
ImageJ National Institutes of 
Health 
https://imag
ej.nih.gov/ij
/download.h
tml 
Cell^ B Soft Imaging System Olympus http://www.
olympus-
sis.com/ 
Other   
N/A   
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Figure S1. Related to Figure 1. Infection promotes development of glucose intolerance and 
insulin resistance in pre-diabetic mice. (A) B6 mice were infected with MCMV or left untreated. 
After one, three, five, seven and twenty-one days, animals were subjected to ITT (n=5). (B) Blood 
glucose concentrations during the clamp. (C-F) Mice were fed for 6 weeks with NCD or HFD. (C) 
Six weeks after start of the diets, FPG was measured (n=60; pooled data of 12 experiments). (D-F) 
Six weeks after start of the diets, mice were subjected to (D) pyruvate tolerance test (PTT, n=5), 
(E) ITT (n=5) and (F) GTT (n=5). (G) Mice that were fed either with NCD or with HFD for 6 
weeks were infected with MCVM or left untreated. One-week p.i. total body weight (n=30; pooled 
data of 6 experiments) or periepididymal fat pad weight (n=5) were measured. (H, I) Mice were 
fed 6 weeks with NCD or HFD and then infected with (H) LCMV or (I) Influenza A. One-week 
p.i. mice were subjected to GTT (n=5). (J) Mice were NCD or HFD fed for 6 weeks and then 
infected with MCMV. Three weeks p.i. MCMV (PFU) titres were determined in indicated tissues 
(n=4-5). (K, L) Mice were fed with NCD or HFD for 6 weeks and then infected with (K) LCMV 
or (L) Influenza A virus or left untreated. Three weeks p.i. mice were subjected to GTT (n=5). (M) 
PAS staining of kidney sections after 24 weeks of feeding. (Green arrow) expansion of mesangial 
matrix, (yellow arrow) increased Bowman capsule size and (red arrow) fibrin cap. (N) MCMV 
immediate early protein (IE1) staining of kidney sections 16 weeks after MCMV infection and start 
of HFD or NCD. (Liver control shows a section stained at day 4 after infection as a positive 
control). (O) MCMV titers (PFU) in liver of animals that were injected with PBS or ganciclovir 
daily, one day after infection with MCMV (n=5) are shown. (A, D-O). Representative of at least 
three experiments is shown. (B) The experiment was performed once. Indicated are means ± s.e.m. 
and statistical significances at * p<0.05, ** p<0.01, ***p<0.001 by (A-F) Student`s t test or (G-I 
and K, L) by ANOVA followed by Bonferroni post-testing and (J) Mann Whitney U test. LD-
level of detection. PFU-plaque forming units. p.i. - post infection. 
 
 
 
 
 
 
Figure S2. Related to Figure 2. Virally-induced IFN- promotes development of IR and GI in 
pre-diabetic mice. (A-D) Mice were NCD- or HFD-fed for 6 weeks. After 6 weeks of HFD, mice 
were treated with CCl4 or paracetamol. (A) Representative pictures of Sirius red staining of livers 
sections are shown, magnification 100 x. (CCl4 promotes development of collagen that is labeled 
red in Sirius red staining). (B) Blood concentrations of ALT after 7 days of treatment with 
paracetamol (n=5).  (C, D) One week after starting with CCl4 or paracetamol treatment mice were 
subjected to GTT (n=5). (E-F) After B6 mice were primed with HFD for 6 weeks, animals were 
infected with MCMV or left untreated. In addition, (E) mice received MCC950 (n=5) or (F) IL-
1 (n=5) depleting antibody every second day starting one day before infection. One week p.i. mice 
were subjected to GTT. (G, H) After 6 weeks of HFD mice were injected every third day with Poly 
I:C. Seven days after initiating Poly I:C treatment (G) peritoneal macrophages were isolated and 
analyzed for expression of MCH class I. (H) mice were subjected to GTT (n=5). (I) Tnfrsf1a
-/- 
mice 
were infected with MCMV after HFD priming for 6 weeks. GTT was performed one week p.i. 
(n=5). (J) B6 mice were infected with MCMV. In addition, mice were treated with IFN- 
neutralization antibody or isotype control every third day, starting one day before infection. Fourth 
and seventh days p.i. viral titers were determined in indicated tissues (n=5). (K) After 6 weeks of 
HFD priming, mice were infected with LCMV or left untreated. In addition, mice received IFN- 
depleting antibody every third day starting one day before infection. After 7 days mice were 
subjected to GTT (n=5). (L) Ifng
-/- 
or B6 (WT) mice were fed with HFD for 6 weeks and then 
infected with MCMV or left untreated. One week after mice were subjected to GTT (shown is fold 
increase in plasma glucose concentrations compared to T0) (n=4-5). (M) After infection with 
MCMV mice were fed with NCD of HFD for 8 weeks and received depleting NK1.1 antibody or 
isotype control every 5 days. After 8 weeks mice were subjected to GTT (n=5). (N) Mice were 
HFD fed for 6 weeks. After 6 weeks of HFD mice were infected with WT MCMV or Δm157. One-
week p.i. mice were subjected to GTT (n=5). Representative of at least three experiments is shown. 
Indicated are means ± s.e.m. and statistical significances at * p<0.05, ** p<0.01 and p<0.001*** 
by (B) Student`s t test or (C-I, K-N) ANOVA followed by Bonferroni post-testing. p.i. - post 
infection. 
 
Figure S3. Related to Figure 3. IFN- induces insulin resistance independently of 
macrophages and hepatocytes. (A) Mice were infected with MCMV or left untreated and placed 
on NCD or HFD. M1 macrophages were quantified after 3 weeks in VAT (n=5). (B) Mice that were 
fed with HFD or NCD for 6 weeks were infected with MCMV. In addition, mice received 
clodronate-loaded or control liposomes one day before infection. One-week p.i. mice were 
subjected to GTT (n=5). (C)
 
Ifngr1ΔHep and littermate control mice were placed on HFD for 6 weeks 
and then infected with MCMV or left untreated. Five days p.i. mice were subjected to ITT and 7 
days p.i. to GTT (n=3-5). Representative of at least three experiments is shown. Indicated are means 
± s.e.m. and statistical significances at * p<0.05, ** p<0.01, ***p<0.001 by ANOVA followed by 
Bonferroni post-testing. p.i. - post infection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S4. Related to Figure 4. Infection increases expression of IFN-  in skeletal muscle. B6 
mice were NCD or HFD fed for 6 weeks, and then infected with MCMV or left untreated. After 
seven days Ifng transcripts were determined in muscle by qPCR (n=5). Representative of two 
experiments with similar results is shown. Indicated are means ± s.e.m. and statistical significances 
at ** p<0.01, ***p<0.001 by ANOVA followed by Bonferroni post-testing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S5. Related to Figure 5. IFN- promotes insulin resistance by downregulation of the 
insulin receptor. (A-B) B6 mice were NCD or HFD fed for 6 weeks, and then infected with 
MCMV or left untreated. After seven days (A) Irs1, Irs2 or (B) Socs1 and Socs3 transcripts were 
determined in muscle samples by qPCR (n=4-5). (C, D) Lean B6 mice were infected with MCMV 
or left uninfected. After five days (C) mRNA or (D) protein amounts were determined in skeletal 
muscle samples by qPCR or immune blot, respectively (n=5). (E) Lean B6 mice were infected with 
LCMV or Influenza A virus or left uninfected. Seven days p.i. transcripts of Insr were determined 
in muscle by qPCR (normalization to uninfected animals is shown) (n=5). (F, G) Mice were fed 
for 6 weeks with NCD or HFD. After 6 weeks mouse recombinant IFN-  or PBS was injected in 
right m. sartorius on daily basis. After 3 days, (F) expression of MHC class II molecules were 
determined on muscle tissue macrophages at the site of of IFN- injection. In addition, (G) mRNAs 
of the Insr were determined in the livers (n=5). Representative of at least three experiments is 
shown. Indicated are means ± s.e.m. and statistical significances at * p<0.05 by (C, D) Student`s t 
test or (A, B, E, G) ANOVA followed by Bonferroni post-testing. p.i. - post infection. InsR – 
insulin receptor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S6. Related to Figure 6. Insulin does not affect proliferation and viability of in vivo 
primed CD8+ T cells. (A) OT-1 CD8 T cells were labelled with CFSE and stimulated in vitro with 
N4 peptide with or without 0.5 mg/ml αCD28, in the presence or absence of 1 U/ml of insulin. 
After two days CFSE dilution was measured as a read-out for proliferation. Red lines are drawn 
for easy analysis of differences in proliferation. (B) OT-1 CD8+ T cells were stimulated in vitro 
with N4 peptide with or without 0.5 mg/ml αCD28, in the presence or absence of 1U/ml of insulin. 
After two and three days viability (Viability dye-) was checked by flow cytometry. Representative 
of at least three experiments is shown (n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S7. Related to Figure 7. DT abrogates production of insulin in Ins2
cre
iDTR mice. (A, 
B) Ins2
cre
 iDTR
 
or iDTR littermate controls were injected twice with DT (once per day), and 24 
hours later challenged with a glucose bolus after 6 hours of fasting. Before glucose administration 
and 30 min later (A) plasma insulin and (B) blood glucose concentrations were measured.  In 
addition, (C) fold increase in blood glucose concentrations was measured 30 min after glucose 
administration (n=3-4). Representative of two experiments with similar results is shown. Indicated 
are means ± s.e.m. and statistical significance at at * p<0.05, ** p<0.01, ***p<0.001 by ANOVA 
followed by Bonferroni post-testing. 
 
Supplemental Information 
 
 
 
 
 
Virus-induced interferon-γ causes insulin resistance in skeletal muscle and derails glycemic 
control in obesity 
 
Marko Šestan, Sonja Marinović, Inga Kavazović, Đurđica Cekinović, Stephan Wueest, Tamara 
Turk Wensveen, Ilija Brizić, Stipan Jonjić, Daniel Konrad, Felix M. Wensveen and Bojan Polić 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Figure S1. Related to Figure 1. Infection promotes development of glucose intolerance and 
insulin resistance in pre-diabetic mice. (A) B6 mice were infected with MCMV or left untreated. 
After one, three, five, seven and twenty-one days, animals were subjected to ITT (n=5). (B) Blood 
glucose concentrations during the clamp. (C-F) Mice were fed for 6 weeks with NCD or HFD. (C) 
Six weeks after start of the diets, FPG was measured (n=60; pooled data of 12 experiments). (D-F) 
Six weeks after start of the diets, mice were subjected to (D) pyruvate tolerance test (PTT, n=5), 
(E) ITT (n=5) and (F) GTT (n=5). (G) Mice that were fed either with NCD or with HFD for 6 
weeks were infected with MCVM or left untreated. One-week p.i. total body weight (n=30; pooled 
data of 6 experiments) or periepididymal fat pad weight (n=5) were measured. (H, I) Mice were 
fed 6 weeks with NCD or HFD and then infected with (H) LCMV or (I) Influenza A. One-week 
p.i. mice were subjected to GTT (n=5). (J) Mice were NCD or HFD fed for 6 weeks and then 
infected with MCMV. Three weeks p.i. MCMV (PFU) titres were determined in indicated tissues 
(n=4-5). (K, L) Mice were fed with NCD or HFD for 6 weeks and then infected with (K) LCMV 
or (L) Influenza A virus or left untreated. Three weeks p.i. mice were subjected to GTT (n=5). (M) 
PAS staining of kidney sections after 24 weeks of feeding. (Green arrow) expansion of mesangial 
matrix, (yellow arrow) increased Bowman capsule size and (red arrow) fibrin cap. (N) MCMV 
immediate early protein (IE1) staining of kidney sections 16 weeks after MCMV infection and start 
of HFD or NCD. (Liver control shows a section stained at day 4 after infection as a positive 
control). (O) MCMV titers (PFU) in liver of animals that were injected with PBS or ganciclovir 
daily, one day after infection with MCMV (n=5) are shown. (A, D-O). Representative of at least 
three experiments is shown. (B) The experiment was performed once. Indicated are means ± s.e.m. 
and statistical significances at * p<0.05, ** p<0.01, ***p<0.001 by (A-F) Student`s t test or (G-I 
and K, L) by ANOVA followed by Bonferroni post-testing and (J) Mann Whitney U test. LD-
level of detection. PFU-plaque forming units. p.i. - post infection. 
 
 
 
 
 
 

Figure S2. Related to Figure 2. Virally-induced IFN-γ promotes development of IR and GI in 
pre-diabetic mice. (A-D) Mice were NCD- or HFD-fed for 6 weeks. After 6 weeks of HFD, mice 
were treated with CCl4 or paracetamol. (A) Representative pictures of Sirius red staining of livers 
sections are shown, magnification 100 x. (CCl4 promotes development of collagen that is labeled 
red in Sirius red staining). (B) Blood concentrations of ALT after 7 days of treatment with 
paracetamol (n=5).  (C, D) One week after starting with CCl4 or paracetamol treatment mice were 
subjected to GTT (n=5). (E-F) After B6 mice were primed with HFD for 6 weeks, animals were 
infected with MCMV or left untreated. In addition, (E) mice received MCC950 (n=5) or (F) IL-
1β (n=5) depleting antibody every second day starting one day before infection. One week p.i. mice 
were subjected to GTT. (G, H) After 6 weeks of HFD mice were injected every third day with Poly 
I:C. Seven days after initiating Poly I:C treatment (G) peritoneal macrophages were isolated and 
analyzed for expression of MCH class I. (H) mice were subjected to GTT (n=5). (I) Tnfrsf1a-/- mice 
were infected with MCMV after HFD priming for 6 weeks. GTT was performed one week p.i. 
(n=5). (J) B6 mice were infected with MCMV. In addition, mice were treated with IFN-γ 
neutralization antibody or isotype control every third day, starting one day before infection. Fourth 
and seventh days p.i. viral titers were determined in indicated tissues (n=5). (K) After 6 weeks of 
HFD priming, mice were infected with LCMV or left untreated. In addition, mice received IFN-γ 
depleting antibody every third day starting one day before infection. After 7 days mice were 
subjected to GTT (n=5). (L) Ifng-/- or B6 (WT) mice were fed with HFD for 6 weeks and then 
infected with MCMV or left untreated. One week after mice were subjected to GTT (shown is fold 
increase in plasma glucose concentrations compared to T0) (n=4-5). (M) After infection with 
MCMV mice were fed with NCD of HFD for 8 weeks and received depleting NK1.1 antibody or 
isotype control every 5 days. After 8 weeks mice were subjected to GTT (n=5). (N) Mice were 
HFD fed for 6 weeks. After 6 weeks of HFD mice were infected with WT MCMV or ∆m157. One-
week p.i. mice were subjected to GTT (n=5). Representative of at least three experiments is shown. 
Indicated are means ± s.e.m. and statistical significances at * p<0.05, ** p<0.01 and p<0.001*** 
by (B) Student`s t test or (C-I, K-N) ANOVA followed by Bonferroni post-testing. p.i. - post 
infection. 
 

Figure S3. Related to Figure 3. IFN-γ induces insulin resistance independently of 
macrophages and hepatocytes. (A) Mice were infected with MCMV or left untreated and placed 
on NCD or HFD. M1 macrophages were quantified after 3 weeks in VAT (n=5). (B) Mice that were 
fed with HFD or NCD for 6 weeks were infected with MCMV. In addition, mice received 
clodronate-loaded or control liposomes one day before infection. One-week p.i. mice were 
subjected to GTT (n=5). (C) Ifngr1∆Hep and littermate control mice were placed on HFD for 6 weeks 
and then infected with MCMV or left untreated. Five days p.i. mice were subjected to ITT and 7 
days p.i. to GTT (n=3-5). Representative of at least three experiments is shown. Indicated are means 
± s.e.m. and statistical significances at * p<0.05, ** p<0.01, ***p<0.001 by ANOVA followed by 
Bonferroni post-testing. p.i. - post infection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Figure S4. Related to Figure 4. Infection increases expression of IFN-γ  in skeletal muscle. B6 
mice were NCD or HFD fed for 6 weeks, and then infected with MCMV or left untreated. After 
seven days Ifng transcripts were determined in muscle by qPCR (n=5). Representative of two 
experiments with similar results is shown. Indicated are means ± s.e.m. and statistical significances 
at ** p<0.01, ***p<0.001 by ANOVA followed by Bonferroni post-testing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Figure S5. Related to Figure 5. IFN-γ promotes insulin resistance by downregulation of the 
insulin receptor. (A-B) B6 mice were NCD or HFD fed for 6 weeks, and then infected with 
MCMV or left untreated. After seven days (A) Irs1, Irs2 or (B) Socs1 and Socs3 transcripts were 
determined in muscle samples by qPCR (n=4-5). (C, D) Lean B6 mice were infected with MCMV 
or left uninfected. After five days (C) mRNA or (D) protein amounts were determined in skeletal 
muscle samples by qPCR or immune blot, respectively (n=5). (E) Lean B6 mice were infected with 
LCMV or Influenza A virus or left uninfected. Seven days p.i. transcripts of Insr were determined 
in muscle by qPCR (normalization to uninfected animals is shown) (n=5). (F, G) Mice were fed 
for 6 weeks with NCD or HFD. After 6 weeks mouse recombinant IFN-γ  or PBS was injected in 
right m. sartorius on daily basis. After 3 days, (F) expression of MHC class II molecules were 
determined on muscle tissue macrophages at the site of of IFN-γ injection. In addition, (G) mRNAs 
of the Insr were determined in the livers (n=5). Representative of at least three experiments is 
shown. Indicated are means ± s.e.m. and statistical significances at * p<0.05 by (C, D) Student`s t 
test or (A, B, E, G) ANOVA followed by Bonferroni post-testing. p.i. - post infection. InsR – 
insulin receptor. 
 
 
 
 
 
 
 
 
 
 
 
 
 

Figure S6. Related to Figure 6. Insulin does not affect proliferation and viability of in vivo 
primed CD8+ T cells. (A) OT-1 CD8 T cells were labelled with CFSE and stimulated in vitro with 
N4 peptide with or without 0.5 mg/ml αCD28, in the presence or absence of 1 U/ml of insulin. 
After two days CFSE dilution was measured as a read-out for proliferation. Red lines are drawn 
for easy analysis of differences in proliferation. (B) OT-1 CD8+ T cells were stimulated in vitro 
with N4 peptide with or without 0.5 mg/ml αCD28, in the presence or absence of 1U/ml of insulin. 
After two and three days viability (Viability dye-) was checked by flow cytometry. Representative 
of at least three experiments is shown (n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Figure S7. Related to Figure 7. DT abrogates production of insulin in Ins2creiDTR mice. (A, 
B) Ins2cre iDTR or iDTR littermate controls were injected twice with DT (once per day), and 24 
hours later challenged with a glucose bolus after 6 hours of fasting. Before glucose administration 
and 30 min later (A) plasma insulin and (B) blood glucose concentrations were measured.  In 
addition, (C) fold increase in blood glucose concentrations was measured 30 min after glucose 
administration (n=3-4). Representative of two experiments with similar results is shown. Indicated 
are means ± s.e.m. and statistical significance at at * p<0.05, ** p<0.01, ***p<0.001 by ANOVA 
followed by Bonferroni post-testing. 
 
